<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transvaginal synthetic mesh: Use in pelvic organ prolapse</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transvaginal synthetic mesh: Use in pelvic organ prolapse</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transvaginal synthetic mesh: Use in pelvic organ prolapse</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emanuel C Trabuco, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John B Gebhart, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda Brubaker, MD, FACOG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Synthetic mesh is frequently used in transabdominal pelvic organ prolapse (POP) repair. However, transvaginal mesh is more controversial. Concerns have been raised about the safety of transvaginal synthetic mesh, which renews debates that attempt to balance the durability of surgical repair with synthetic mesh against the risk of mesh-related complications.</p><p>This topic will discuss issues related to transvaginal mesh for surgical treatment of POP. Related discussions on synthetic mesh for the treatment of urinary incontinence, complications of synthetic vaginal mesh, and management of mesh exposure and pain are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115450.html" rel="external">"Transvaginal synthetic mesh: Use in stress urinary incontinence (SUI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115279.html" rel="external">"Transvaginal synthetic mesh: Complications and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17175.html" rel="external">"Transvaginal synthetic mesh: Management of exposure and pain following pelvic surgery"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender expansive individuals.</p><p class="headingAnchor" id="H980652777"><span class="h1">MESH PRODUCTS</span></p><p class="headingAnchor" id="H103235368"><span class="h2">Synthetic mesh</span><span class="headingEndMark"> — </span>Synthetic materials are available as both absorbable and nonabsorbable mesh. These reconstructive materials can be part of trocar-guided synthetic mesh inserts or kits  (<a class="graphic graphic_figure graphicRef85544" href="/z/d/graphic/85544.html" rel="external">figure 1</a>). Nonabsorbable synthetic materials are generally described by type and classified based on pore size and weave [<a href="#rid1">1</a>]. Type 1 macroporous monofilament polypropylene mesh is typically preferred for reconstructive pelvic surgery [<a href="#rid2">2</a>]. Type 1 mesh can be further subdivided into heavy-, mid-, and lightweight materials. There is preliminary evidence suggesting that heavyweight synthetic mesh is associated with more frequent graft-related complications and interventions compared with lightweight mesh [<a href="#rid3">3-5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2879.html" rel="external">"Reconstructive materials used in surgery: Classification and host response"</a>.)</p><p class="headingAnchor" id="H314234"><span class="h2">Transvaginal mesh kits</span><span class="headingEndMark"> — </span>We do not use commercial mesh kits (referred to as mesh kits or trocar-guided mesh kits  (<a class="graphic graphic_figure graphicRef85544" href="/z/d/graphic/85544.html" rel="external">figure 1</a>)) because of high rates of complication and reoperation without a demonstrated benefit in patient awareness of prolapse recurrence [<a href="#rid6">6,7</a>]. In a meta-analysis of three trials that compared native tissue repair with a variety of mesh kits for surgical prolapse repair, of the women who received a mesh kit, 18 percent had a mesh exposure and 9 percent underwent surgical correction of mesh exposure [<a href="#rid6">6</a>]. The total reoperation rate was three times greater for women with mesh kits than women with native tissue repair (relative risk [RR] 3.1, 95% CI 1.3-7.3). While the prolapse recurrence rate on examination was higher for the native tissue group than the mesh group (RR 2.0, 95% CI 1.3-3.1), there was no difference in patient perception of prolapse between the groups (RR 1.3, 95% CI 0.6-1.7). Thus, the women receiving mesh kits had higher complication rates but similar outcomes from the patients' assessments. Challenges to definitive conclusions based on the body of evidence include a limited duration of follow-up and limited data on nonsurgical patient outcomes (ie, a woman may have a recurrent bulge but not elect repeat surgical repair).</p><p>Early iterations of mesh kits involved insertion of precut graft material between the vaginal epithelium and underlying fascia. However, this approach results in split thickness of the overlying vaginal tissue, which may contribute to mesh erosion. Proponents of mesh kits now suggest a full thickness dissection, placing the mesh between the fascia and underlying organ (bladder/rectum), in attempts to decrease mesh erosion. Supporting data are not yet available. (See  <a class="medical medical_review" href="/z/d/html/115279.html" rel="external">"Transvaginal synthetic mesh: Complications and risk factors", section on 'Surgical technique'</a>.)</p><p>The graft is suspended in a tension-free manner with polypropylene mesh arms that are typically passed through a supportive connective tissue structure (eg, arcus tendineus fascia, obturator membrane, iliococcygeus fascia, or sacrospinous ligaments)  (<a class="graphic graphic_figure graphicRef85544" href="/z/d/graphic/85544.html" rel="external">figure 1</a>). Transvaginal mesh kits are available in different versions that treat one or multiple anatomic sites within the same procedure [<a href="#rid8">8-12</a>]. </p><p class="headingAnchor" id="H1902173189"><span class="h1">ISSUES SURROUNDING SYNTHETIC MESH FOR POP</span></p><p class="headingAnchor" id="H4063579096"><span class="h2">Advisory statements</span><span class="headingEndMark"> — </span>Medical societies and regulatory agencies around the world have released statements regarding the use of synthetic mesh in gynecologic surgery [<a href="#rid2">2,13-18</a>]. In 2019, the US Food and Drug Administration (FDA) banned the sale and distribution of surgical mesh for use in transvaginal anterior compartment prolapse (ie, cystocele) repair because they were unable to confirm that the probable benefits outweighed the probable risks [<a href="#rid19">19</a>]. The ban followed the 2016 reclassification of transvaginal synthetic mesh from a class II to a class III (ie, high risk) device [<a href="#rid17">17</a>]. The classification change was made in response to increased reporting of adverse events from mesh-based transvaginal POP repairs [<a href="#rid20">20</a>]. While the 2019 National Institute for Health and Care Excellence (NICE) <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fng123%2Fresources%2Furinary-incontinence-and-pelvic-organ-prolapse-in-women-management-pdf-66141657205189&amp;token=RlI58myTjJJ%2Ffndz4fgg9C3TXQak3Wnvk6dFxlSIxC%2FgfYKWq%2BnBy2G%2FfWOJMPc9ZbTIvzyzuSVGc95dLrSHqUgWxuORvuEi5AagCxp8AYiUWrVuTk1KFt9GfhJun6zAdgo7yB%2F%2FvgG%2F77Udg%2FsQrOZLkeFMgx4%2FvzyaHwdFgCk%3D&amp;TOPIC_ID=8077" target="_blank">guideline</a> did not ban the use of synthetic mesh for transvaginal prolapse repair, the organization did advise use of a decision aid for women considering surgery, detailed counseling for women considering mesh-based procedures, and tracking of data on surgery and complications [<a href="#rid18">18</a>]. Of note, the FDA mesh ban does <strong>not</strong> apply to transvaginal mesh used in the treatment of stress urinary incontinence or to transabdominal mesh for prolapse repair [<a href="#rid21">21</a>].</p><p>For women who have already had transvaginal mesh inserted for POP repair, the FDA advised they continue with their annual and other routine check-ups and follow-up care [<a href="#rid17">17</a>]. No action is needed if the patient is satisfied with her surgery and is not having complications or symptoms. Patients should notify their health care professionals if they have complications or symptoms, including persistent vaginal bleeding or discharge, pelvic or groin pain, or pain with sex. They should also let their health care professional know if they have surgical mesh, especially if they plan to have another surgery or other medical procedures. For English women desiring mesh removal because of complications, a network of specialist mesh removal centers is being established [<a href="#rid22">22</a>]. Mesh related complications and removal are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115279.html" rel="external">"Transvaginal synthetic mesh: Complications and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17175.html" rel="external">"Transvaginal synthetic mesh: Management of exposure and pain following pelvic surgery"</a>.) </p><p></p><p>A review of the original FDA approval process for 61 mesh POP devices reported approval for all was based on claimed equivalence to the 1985 Mersilene Mesh (Ethicon) and the 1996 ProteGen Sling (Boston Scientific) [<a href="#rid23">23</a>]. No clinical trial data were available at the time of the approval of the 61 devices. Published trial data were reported a median of 5 years after device approval (range 1 to 14 years).</p><p class="headingAnchor" id="H15375039"><span class="h2">Recommendations to health care providers</span><span class="headingEndMark"> — </span>Regulatory agencies around the globe have released recommendations on the use of synthetic mesh in treating POP [<a href="#rid13">13-16,18,19,24</a>]. Additionally, prior to the 2019 FDA decision to remove transvaginal mesh from the United States market, surgical societies had published guidelines regarding surgeon training [<a href="#rid25">25,26</a>]. Some key points are:</p><p class="bulletIndent1"><span class="glyph">●</span>Should a clinician wish to use surgical mesh to treat POP, awareness of the FDA restrictions and specialized training for the specific mesh technique are paramount [<a href="#rid13">13,14,24,25,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In most cases, POP can be treated successfully without mesh and thus can avoid the risk of mesh-related complications [<a href="#rid13">13,14,24</a>]. However, the surgeon must also acknowledge that approximately 20 percent of women undergoing any type of prolapse repair will experience prolapse recurrence [<a href="#rid28">28-30</a>]. Thus, choose transvaginal mesh-based repairs only after weighing the risks and benefits of surgery with mesh versus all surgical and nonsurgical alternatives [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Understand that having a transvaginal mesh surgery may put the patient at risk for requiring additional surgery or for the development of new complications, and counsel the patient accordingly [<a href="#rid13">13,14,24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If mesh is to be used for POP repair, transabdominal mesh placement may result in lower rates of mesh complications compared with transvaginal POP surgery with mesh [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Synthetic mesh should not routinely be used for repair of posterior vaginal prolapse because mesh use in this location does not improve outcomes and is associated with increased risk of complications [<a href="#rid27">27,31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While transvaginal synthetic mesh repairs of anterior wall prolapse improve subjective outcomes and anatomic success rates, women with mesh-based anterior repairs have the same risk of undergoing repeat prolapse surgery and an increased risk of mesh-related complications compared with women having native tissue repairs [<a href="#rid27">27,31</a>]. Thus, mesh repairs of anterior prolapse are limited to women with a high risk of prolapse recurrence in whom the potential benefits justify the risks [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inform patients that implantation of surgical mesh is permanent and that some mesh-related complications may require additional surgery that may or may not correct the complication [<a href="#rid13">13,14,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians performing transvaginal mesh POP repairs should remain vigilant for potential adverse events from the mesh, especially exposure and infection [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/115279.html" rel="external">"Transvaginal synthetic mesh: Complications and risk factors", section on 'Complications by procedure'</a>.)</p><p></p><p class="headingAnchor" id="H15375071"><span class="h2">Professional society guidelines</span><span class="headingEndMark"> — </span>Several gynecologic surgical societies have released guidelines regarding transvaginal placement of surgical mesh for POP repair [<a href="#rid25">25,33-38</a>], including:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iuga.org%2F&amp;token=IxD3u0MI4L59NDWpJ3QysDls0Y45d290nlqN95tEDSc%3D&amp;TOPIC_ID=8077" target="_blank">International Urogynecological Association</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.augs.org%2Fclinical-practice%2Fguidelines%2F&amp;token=j%2BtF41plvYHq0KcVLVNCggn5a7vuh2e9R5S%2FOf625RHUtDYJ%2Bg8klX%2FWjTZlPJu71A0BTKKMPVYMo8Ukkay0aw%3D%3D&amp;TOPIC_ID=8077" target="_blank">American Urogynecologic Society</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fsogc.org%2F%3Fs%3Dpelvic%2Borgan%2Bprolapse&amp;token=N6j1DJrwGs%2BHtbf1tSu7JUKN0%2FXgjl8mS1f93d8gk5VGiSGOv3cDhcl%2FmEGhNSr2&amp;TOPIC_ID=8077" target="_blank">Society of Obstetricians and Gynaecologists of Canada</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.sufuorg.com%2FProfessional-Resources.aspx&amp;token=uN3kZjtGDxmJrqpyNQW247JaXihvbCkC2OoDLMz97UlgUOkfdTTd7V7F1hqvi3szP91Btv31kT3z3dPR%2BlYnSg%3D%3D&amp;TOPIC_ID=8077" target="_blank">Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rcog.org.uk%2Fglobalassets%2Fdocuments%2Fguidelines%2Fgtg-46.pdf&amp;token=%2Fbg8%2Bihb4d68nY11a6ogDbreiyP%2BADGM2%2BKBpiJcg%2BsZUng79Z8Y8E%2Bvagj6fXs3b8a4hhltC1Hf3eGs3hzXSqNwnQvxJBpZsG7m%2BnXYfE0%3D&amp;TOPIC_ID=8077" target="_blank">British Society of Urogynaecologists and Royal College of Obstetricians and Gynaecologists</a></p><p></p><p class="headingAnchor" id="H1233886010"><span class="h1">DECISION TO USE SYNTHETIC MESH</span><span class="headingEndMark"> — </span>In general, native tissue repair <strong>without</strong> synthetic mesh is the preferred approach for <strong>transvaginal</strong> POP surgery because of the higher risk of complications and repeat surgery with mesh-based repairs [<a href="#rid28">28,31,39-44</a>]. Challenges in comparing native tissue with synthetic mesh repairs include variations in types of anatomic defects and repair surgeries, types of synthetic materials, definitions of success, and duration of follow-up. For example, a prospective cohort study reported noninferiority of native tissue prolapse repair compared with transvaginal mesh repair for the objective end point [<a href="#rid43">43</a>]. However, the mesh arm was superior to native tissue repair at 36 months for the subjective end point (POP-Q points Ba &lt;0, C &lt;1/2 total vaginal length, no vaginal bulging symptoms, and no retreatment). There was no difference in serious adverse events between groups, with a 4.9 percent mesh exposure rate. Whether or not improved efficacy detected in some comparative trials for mesh-based repairs outweighs mesh-related risks is a point of debate [<a href="#rid31">31,40</a>]. However, in the prospective cohort study, there were no differences in subjective success, retreatment for recurrence, and complications between the two groups [<a href="#rid43">43</a>]. Participants in this study were over 60 years of age (mean age 66.6 and 62.4 years, respectively).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors influencing use of transvaginal mesh</strong> – The choice of native tissue or synthetic mesh repair must be tailored to the individual, include their preferences, and consider the patient's type of prolapse, risk of prolapse recurrence, planned surgical route (vaginal or abdominal), surgery sequence (primary or repeat), and availability of synthetic mesh products. Surgical mesh for transvaginal POP repair is available for use in European and other countries in carefully selected and counseled patients but is banned in Australia, New Zealand, Ireland, and Scotland. The United Kingdom has placed a national pause on the use of surgical mesh for POP. Clinicians should understand their local guidelines as some countries have also banned the use of transvaginal mesh/tapes for the treatment of stress urinary incontinence (SUI). In the United States, transvaginal mesh for the treatment of POP has been removed from the market based on a lack of demonstrated superiority compared with native tissue approaches [<a href="#rid2">2,13-16,18,19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – The surgical approach for POP should be tailored to the individual, taking into account her preferences and anatomic challenges. We take the following approaches:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Typical risk of prolapse recurrence</strong> – For patients with a typical risk of recurrent prolapse and who are undergoing a primary repair, we perform transvaginal prolapse repair using native tissue. We counsel women that, while native tissue repairs are associated with higher rates of recurrent prolapse and repeat prolapse surgery, the overall risk for repeat surgery is lower because women with native tissue repairs will not have synthetic mesh complications, such as mesh exposure, requiring reoperation. We believe the body of evidence, exemplified by the studies below, favor no or limited use of mesh-based primary repairs outside of clinical trials. (See  <a class="medical medical_review" href="/z/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent2">Supporting data include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In an observational study from a New York state database including over 41,000 women that compared the rates of clinically significant mesh complications and repeat surgery to treat mesh-related complications within 12 months of the original surgery, vaginal mesh repairs had higher rates of mesh erosion and repeat surgery compared with non-mesh vaginal repairs, regardless of concomitant sling surgery for SUI (percentages of women having repeat surgery were 5.6 percent for vaginal mesh plus sling, 4.3 percent for vaginal mesh alone, 3.8 percent for non-mesh prolapse repair with sling, and 2.5 percent for sling alone) [<a href="#rid39">39</a>]. Strengths of the study included the large number of women, use of a statewide database (which helps capture women who change providers), and use of repeat surgery as an end point (and thus focuses on erosions that require intervention and not asymptomatic mesh exposures). Of note, women with a history of prior POP or SUI surgery were excluded from this study. Importantly, this study also reconfirmed the relative safety of synthetic mesh suburethral slings for urinary incontinence.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A European trial including over 1300 women reported that mesh-augmented repairs for POP were associated with a greater than 1 in 10 risk of mesh-related complications but demonstrated no improvement in outcome [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased risk of prolapse recurrence</strong> – For patients who have increased risk of recurrent prolapse (eg, those with procidentia or with a known connective tissue abnormality) or who have prior unsuccessful primary repair <strong>and</strong> who desire transvaginal surgical repair, surgical correction with synthetic mesh, where available, is reasonable in carefully counseled women because synthetic mesh repair is associated with lower rates of recurrent prolapse and repeat prolapse surgery compared with native tissue repair. We suggest counseling these women that the risk of mesh-related complications and overall repeat surgery rates for mesh-related complications are higher with synthetic mesh repairs [<a href="#rid28">28,31</a>].</p><p></p><p class="bulletIndent2">Our approach is based on evidence from a systematic review and meta-analysis comparing transvaginal mesh or grafts with native tissue repair for vaginal prolapse that reported the following outcomes [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the analysis of 21 trials comparing synthetic transvaginal mesh with native tissue repair for POP, the risk of recurrent prolapse, defined as stage 2 or greater prolapse on examination at any vaginal site, was lower in women undergoing synthetic mesh repairs than for native tissue repairs (relative risk [RR] 0.40, 95% CI 0.30-0.53, n = 2494 women). When the subanalysis was limited to women with anterior compartment repair, synthetic mesh repairs were associated with an even lower risk of recurrent prolapse compared with native tissue repairs (RR 0.33, 95% CI 0.26-0.40, 15 trials, n = 1748 women).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the analysis of 12 trials assessing repeat prolapse surgery, repeat surgery for any prolapse was less common in women undergoing synthetic mesh repairs than for native tissue repairs (RR 0.53, 95% CI 0.31-0.88, n = 1675 women).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the analysis of seven trials assessing the combined rates of repeat surgery (ie, repeat surgery for prolapse, urinary incontinence, or mesh exposure), women with synthetic mesh repairs had more than double the risk of repeat surgery compared with women with native tissue repairs (RR 2.40, 95% CI 1.51-3.81, n = 867) because of the increase in mesh-related complications that required surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Data limitations</strong> – The above approaches are based on data with inherent limitations and thus may change as the body of evidence continues to evolve. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of follow-up</strong> – One major limitation of the studies in the above meta-analysis is their relatively short period of follow-up. Data are needed comparing the long-term cumulative risk of surgery for mesh-related complications with the risk of repeat surgery for recurrent prolapse after a native tissue repair. In a five-year prospective cohort study of a vaginal mesh support kit, optimal apical support decreased from 94 percent at one year to 83 percent at five years [<a href="#rid45">45</a>]. It is possible that the risks will cross at some future time point. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unknown impact of apical repair</strong> – A number of the trials included in the above meta-analysis did not allow for concomitant apical repair in the native tissue arm; hence, it remains unclear if, and by how much, this omission contributed to the above findings. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgeon volume</strong> – The studies did not include information on surgeon volume. As with other gynecologic surgeries, it is possible that surgeon volume will impact complication and success rates [<a href="#rid46">46-48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical route and impact of apical prolapse</strong> – Prolapse repair with synthetic mesh can be performed via transabdominal or transvaginal routes. The choice of route partly depends on the anatomic defects that are present. For those with concurrent apical prolapse, we prefer abdominal repair (open, traditional laparoscopic, or robot-assisted prolapse repair) with macroporous type 1 synthetic mesh. However, others prefer native tissue repair [<a href="#rid44">44</a>]. Discussion of the benefits and risks of abdominal and vaginal repair is presented elsewhere.</p><p></p><p class="bulletIndent1">Specific discussions of native tissue and synthetic mesh repair by anatomic site of prolapse are presented separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8084.html" rel="external">"Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse", section on 'Use of reconstructive materials'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8083.html" rel="external">"Surgical management of posterior vaginal defects", section on 'Graft augmentation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8073.html" rel="external">"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)", section on 'Surgical planning'</a>.)</p><p></p><p class="headingAnchor" id="H1978412608"><span class="h1">ALTERNATIVES TO SYNTHETIC MESH</span><span class="headingEndMark"> — </span>It is not necessary to use any form of biologic or synthetic material to repair POP. Native tissues repairs are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8084.html" rel="external">"Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse", section on 'Midline defect repair (anterior colporrhaphy)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8083.html" rel="external">"Surgical management of posterior vaginal defects", section on 'Choice of procedure'</a>.)</p><p></p><p>While biologic materials are available, we do not use allograft or xenograft materials in our practice for POP treatment because they do not appear to mitigate complications and have mostly underperformed compared with synthetic materials [<a href="#rid49">49-51</a>]. Other types of reconstructive materials (autograft, allograft, xenograft) are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2879.html" rel="external">"Reconstructive materials used in surgery: Classification and host response", section on 'Types of materials'</a>.)</p><p class="headingAnchor" id="H314664"><span class="h1">PREOPERATIVE PREPARATION</span></p><p class="headingAnchor" id="H314673"><span class="h2">Informed consent</span><span class="headingEndMark"> — </span>A detailed preoperative informed consent process is of paramount importance to establish appropriate patient expectations. The patient is counseled regarding expected benefit compared with risk of complications with mesh use and that polypropylene mesh is permanent. Alternative nonsurgical options and other surgical treatments are reviewed. Potential complications of synthetic mesh that may require additional intervention and may not be completely resolved with mesh removal are discussed. This discussion is documented on the procedure consent form and in the medical record.</p><p class="headingAnchor" id="H314709"><span class="h2">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>We agree with professional society guidelines [<a href="#rid52">52,53</a>] recommending antibiotic prophylaxis for all procedures for treatment of POP.</p><p>Antibiotic prophylaxis has typically been used for procedures involving reconstructive materials; there are few data regarding the infection rate if antibiotics are not administered. The utility of antibiotic prophylaxis is based upon indirect data from other procedures involving mesh. Mesh use in inguinal or femoral hernia repair is the most similar clinical use. A meta-analysis of six randomized trials in which reconstructive material was used for inguinal hernia repair demonstrated that infection rates were significantly lower when antimicrobial prophylaxis was administered [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery", section on 'Antibiotic prophylaxis'</a>.)</p><p>For transvaginal placement of reconstructive materials, the risk of infection is likely higher than with inguinal or femoral hernia repair. A vaginal incision is classified as a clean-contaminated procedure, which is associated with a 2.4 to 7.7 percent rate of surgical site infection, and antibiotic prophylaxis is typically used for this risk of infection. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Wound classification'</a>.)</p><p>Use of reconstructive materials does not affect the need for antibiotic prophylaxis of bacterial endocarditis. </p><p class="headingAnchor" id="H1569762403"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122885.html" rel="external">"Society guideline links: Gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical materials for pelvic organ prolapse repair</strong> – Materials available for the treatment of pelvic organ prolapse (POP) include synthetic mesh, transvaginal mesh kits, and autologous grafts. (See <a class="local">'Mesh products'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Synthetic mesh</strong> – Macroporous polypropylene mesh is the most common type of synthetic mesh used for POP repair. Materials with microporous structure are associated with increased complications rates and should be avoided. (See <a class="local">'Synthetic mesh'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biologic materials</strong> – Biologic materials (xenograft and allografts) are less commonly used because they are less effective for treatment of POP compared with synthetic materials yet have comparable rates of complications. (See <a class="local">'Alternatives to synthetic mesh'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Commercial synthetic mesh kits</strong> – Commercial transvaginal mesh kits for POP (referred to as mesh kits or trocar-guided mesh kits) are rarely used because of high complication rates. (See <a class="local">'Transvaginal mesh kits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advisories for use of synthetic vaginal mesh</strong> – Some countries have banned the use of mesh for <strong>transvaginal</strong> POP repair. Clinicians should understand their local guidelines. The FDA has restricted sale of transvaginal mesh for POP repair. Other regulatory agencies have issued statements regarding use of synthetic mesh in gynecologic surgery and made recommendations for health care providers on training, mesh use, patient counseling, and postoperative follow-up. (See <a class="local">'Advisory statements'</a> above and <a class="local">'Recommendations to health care providers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to use synthetic mesh</strong> – In general, native tissue repair <strong>without</strong> synthetic mesh is the preferred approach for transvaginal POP surgery because of the higher risk of complications and repeat surgery with mesh-based repairs. The approach is tailored to the patient. (See <a class="local">'Decision to use synthetic mesh'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with average risk of prolapse recurrence</strong> – For women with a typical risk of recurrent prolapse who are undergoing primary transvaginal POP repair, we recommend native tissue reconstruction rather than synthetic mesh repair (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Although native tissue repairs are associated with higher rates of recurrent prolapse on examination and repeat prolapse surgery compared with synthetic mesh repairs, native tissue surgery does not have synthetic mesh complications and thus has lower overall reoperation rates. (See <a class="local">'Decision to use synthetic mesh'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with increased risk of prolapse recurrent</strong> – For women who have experienced recurrence after prior reconstructive surgery or who have high future risk of prolapse, we offer transabdominal prolapse repair with synthetic mesh, particularly if the woman has concurrent apical prolapse. We do not recommend the use of transvaginal mesh for POP outside of clinical trials in lieu of the 2019 US Food and Drug Administration (FDA) ban of these products. (See <a class="local">'Decision to use synthetic mesh'</a> above.)</p><p></p><p class="bulletIndent2">In countries where transvaginal mesh for POP repair is available, we believe transvaginal mesh repair of POP may be considered by experienced surgeons after carefully counseling patients. Transabdominal synthetic mesh repairs are associated with lower rates of recurrent prolapse and repeat prolapse surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical preparation</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient consent</strong> – A detailed informed consent process should be documented before using synthetic mesh. The informed consent includes information regarding (1) benefit and risk of complications with mesh use, (2) permanence of polypropylene mesh, (3) alternative nonsurgical options and other surgical treatments, and (4) potential complications of synthetic mesh, which may require additional intervention and may not completely resolve with mesh removal. (See <a class="local">'Informed consent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic prophylaxis</strong> – We recommend antibiotic prophylaxis for surgical site infection for surgical procedures for treatment of POP that utilize surgical mesh (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Antibiotic prophylaxis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">US Food and Drug Administration. 2016 Information for health care providers for stress urinary incontinence. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm345221.htm (Accessed on January 12, 2016).</li><li><a class="nounderline abstract_t">Chapple CR, Cruz F, Deffieux X, et al. Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. Eur Urol 2017.</a></li><li><a class="nounderline abstract_t">Page AS, Cattani L, Pacquée S, et al. Long-term Data on Graft-Related Complications After Sacrocolpopexy With Lightweight Compared With Heavier-Weight Mesh. Obstet Gynecol 2023; 141:189.</a></li><li><a class="nounderline abstract_t">Durst PJ, Heit MH. Polypropylene Mesh Predicts Mesh/Suture Exposure After Sacrocolpopexy Independent of Known Risk Factors: A Retrospective Case-Control Study. Female Pelvic Med Reconstr Surg 2018; 24:360.</a></li><li><a class="nounderline abstract_t">van Zanten F, van Iersel JJ, Paulides TJC, et al. Long-term mesh erosion rate following abdominal robotic reconstructive pelvic floor surgery: a prospective study and overview of the literature. Int Urogynecol J 2020; 31:1423.</a></li><li><a class="nounderline abstract_t">Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2013; :CD004014.</a></li><li><a class="nounderline abstract_t">Maher C, Feiner B, Baessler K, et al. Surgery for women with anterior compartment prolapse. Cochrane Database Syst Rev 2016; 11:CD004014.</a></li><li><a class="nounderline abstract_t">Elmér C, Altman D, Engh ME, et al. Trocar-guided transvaginal mesh repair of pelvic organ prolapse. Obstet Gynecol 2009; 113:117.</a></li><li><a class="nounderline abstract_t">Simon M, Debodinance P. Vaginal prolapse repair using the Prolift kit: a registry of 100 successive cases. Eur J Obstet Gynecol Reprod Biol 2011; 158:104.</a></li><li><a class="nounderline abstract_t">Lo TS. One-year outcome of concurrent anterior and posterior transvaginal mesh surgery for treatment of advanced urogenital prolapse: case series. J Minim Invasive Gynecol 2010; 17:473.</a></li><li><a class="nounderline abstract_t">Pacquée S, Palit G, Jacquemyn Y. Complications and patient satisfaction after transobturator anterior and/or posterior tension-free vaginal polypropylene mesh for pelvic organ prolapse. Acta Obstet Gynecol Scand 2008; 87:972.</a></li><li><a class="nounderline abstract_t">Khandwala S, Jayachandran C. Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial. Int Urogynecol J 2011; 22:1405.</a></li><li class="breakAll">European Commission Scientific Committee on Emerging and Newly Identified Health Risks. Opinion on the safety of surgical meshes used in urogynecological surgery. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_049.pdf (Accessed on January 12, 2016).</li><li class="breakAll">Health Canada Advisory. Complications associated with transvaginal implantation of surgical mesh for the treatment of pelvic organ prolapse and stress urinary incontinence. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39475a-eng.php (Accessed on January 13, 2016).</li><li class="breakAll">Scottish Independent Review of the use, safety and efficacy of transvaginal mesh implants in the treatment of stress
urinary incontinence and pelvic organ prolapse in women. Final Report. March 2017. http://www.gov.scot/Resource/0051/00515856.pdf (Accessed on November 30, 2017).</li><li class="breakAll">The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Polypropylene vaginal mesh implants for vaginal prolapse. Renewed November 2016. www.ranzcog.edu.au/getattachment/Statements-Guidelines/Gynaecology/Polypropylene-Vaginal-Mesh-Implants-for-Vaginal-Pr/Polypropylene-vaginal-mesh-implants-for-vaginal-prolapse-(C-Gyn-20)-Review-November-2016.pdf?lang=en-AU&amp;ext=.pdf (Accessed on November 30, 2017).</li><li class="breakAll">US Food and Drug Administration. Reclassification for surgical mesh to repair pelvic organ prolapse. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm479732.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on January 05, 2016).</li><li class="breakAll">Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline. National Institute for Health and Care Excellence. April 2019 www.nice.org.uk/guidance/ng123/resources/urinary-incontinence-and-pelvic-organ-prolapse-in-women-management-pdf-66141657205189 (Accessed on April 22, 2019).</li><li class="breakAll">Urogynecologic Surgical Mesh Implants. U.S. Food and Drug Administration. April 2019. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.htm (Accessed on April 18, 2019).</li><li class="breakAll">Urogynecologic surgical mesh: Update on the safety and effectiveness of transvaginal placement for pelvic organ prolapse. US Food and Drug Administration, 2011.</li><li class="breakAll">US Food and Drug Administration. Obstetrical and gynecological devices: Reclassification of surgical instrumentation for use with urogynecologic surgical mesh, January 2017. https://www.federalregister.gov/documents/2017/01/06/2016-31862/obstetrical-and-gynecological-devices-reclassification-of-surgical-instrumentation-for-use-with (Accessed on October 23, 2017).</li><li><a class="nounderline abstract_t">Dyer C. England set to open specialist surgical mesh removal centres in April. BMJ 2020; 371:m4589.</a></li><li><a class="nounderline abstract_t">Heneghan CJ, Goldacre B, Onakpoya I, et al. Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. BMJ Open 2017; 7:e017125.</a></li><li class="breakAll">US Food and Drug Administration. Information for health care providers for pelvic organ prolapse. Updated January 2017. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm345204.htm (Accessed on November 30, 2017).</li><li><a class="nounderline abstract_t">American Urogynecologic Society’s Guidelines Development Committee. Guidelines for providing privileges and credentials to physicians for transvaginal placement of surgical mesh for pelvic organ prolapse. Female Pelvic Med Reconstr Surg 2012; 18:194.</a></li><li><a class="nounderline abstract_t">Murphy M, Society of Gynecologic Surgeons Systematic Review Group. Clinical practice guidelines on vaginal graft use from the society of gynecologic surgeons. Obstet Gynecol 2008; 112:1123.</a></li><li><a class="nounderline abstract_t">Practice Bulletin No. 176: Pelvic Organ Prolapse. Obstet Gynecol 2017; 129:e56.</a></li><li><a class="nounderline abstract_t">Nygaard I, Brubaker L, Zyczynski HM, et al. Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA 2013; 309:2016.</a></li><li><a class="nounderline abstract_t">Barber MD, Brubaker L, Nygaard I, et al. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol 2009; 114:600.</a></li><li><a class="nounderline abstract_t">Barber MD, Brubaker L, Burgio KL, et al. Comparison of 2 transvaginal surgical approaches and perioperative behavioral therapy for apical vaginal prolapse: the OPTIMAL randomized trial. JAMA 2014; 311:1023.</a></li><li><a class="nounderline abstract_t">Maher C, Feiner B, Baessler K, et al. Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse. Cochrane Database Syst Rev 2016; 2:CD012079.</a></li><li><a class="nounderline abstract_t">Karram M, Maher C. Surgery for posterior vaginal wall prolapse. Int Urogynecol J 2013; 24:1835.</a></li><li><a class="nounderline abstract_t">Committee on Gynecologic Practice. Committee Opinion no. 513: Vaginal placement of synthetic mesh for pelvic organ prolapse. Obstet Gynecol 2011; 118:1459.</a></li><li><a class="nounderline abstract_t">Davila GW. Optimizing safety and appropriateness of graft use in pelvic reconstructive surgery: introduction to the 2nd IUGA Grafts Roundtable. Int Urogynecol J 2012; 23 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Davila GW, Baessler K, Cosson M, Cardozo L. Selection of patients in whom vaginal graft use may be appropriate. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J 2012; 23 Suppl 1:S7.</a></li><li><a class="nounderline abstract_t">Slack M, Ostergard D, Cervigni M, Deprest J. A standardized description of graft-containing meshes and recommended steps before the introduction of medical devices for prolapse surgery. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J 2012; 23 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Winters JC, Jacquetin B, Castro R. Credentialing for transvaginal mesh placement--a case for "added qualification" in competency. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J 2012; 23 Suppl 1:S27.</a></li><li><a class="nounderline abstract_t">Miller D, Milani AL, Sutherland SE, et al. Informed surgical consent for a mesh/graft-augmented vaginal repair of pelvic organ prolapse. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J 2012; 23 Suppl 1:S33.</a></li><li><a class="nounderline abstract_t">Chughtai B, Barber MD, Mao J, et al. Association Between the Amount of Vaginal Mesh Used With Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence. JAMA Surg 2017; 152:257.</a></li><li><a class="nounderline abstract_t">Glazener CM, Breeman S, Elders A, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet 2017; 389:381.</a></li><li><a class="nounderline abstract_t">Chughtai B, Mao J, Asfaw TS, et al. Long-term Device Outcomes of Mesh Implants in Pelvic Organ Prolapse Repairs. Obstet Gynecol 2020; 135:591.</a></li><li><a class="nounderline abstract_t">Reid FM, Aucott L, Glazener CMA, et al. PROSPECT: 4- and 6-year follow-up of a randomised trial of surgery for vaginal prolapse. Int Urogynecol J 2023; 34:67.</a></li><li><a class="nounderline abstract_t">Kahn B, Varner RE, Murphy M, et al. Transvaginal Mesh Compared With Native Tissue Repair for Pelvic Organ Prolapse. Obstet Gynecol 2022; 139:975.</a></li><li><a class="nounderline abstract_t">Padoa A, Braga A, Fligelman T, et al. European Urogynaecological Association Position Statement: Pelvic Organ Prolapse Surgery. Urogynecology (Phila) 2023; 29:703.</a></li><li><a class="nounderline abstract_t">Rahkola-Soisalo P, Mikkola TS, Altman D, et al. Pelvic Organ Prolapse Repair Using the Uphold Vaginal Support System: 5-Year Follow-Up. Female Pelvic Med Reconstr Surg 2019; 25:200.</a></li><li><a class="nounderline abstract_t">Nüssler E, Eskildsen JK, Nüssler EK, et al. Impact of surgeon experience on routine prolapse operations. Int Urogynecol J 2018; 29:297.</a></li><li><a class="nounderline abstract_t">Morgan DM, Pulliam S, Adam RA, et al. Analysis of High-, Intermediate-, and Low-Volume Surgeons When Performing Hysterectomy for Uterovaginal Prolapse. Female Pelvic Med Reconstr Surg 2016; 22:43.</a></li><li><a class="nounderline abstract_t">Kelly EC, Winick-Ng J, Welk B. Surgeon Experience and Complications of Transvaginal Prolapse Mesh. Obstet Gynecol 2016; 128:65.</a></li><li><a class="nounderline abstract_t">FitzGerald MP, Mollenhauer J, Bitterman P, Brubaker L. Functional failure of fascia lata allografts. Am J Obstet Gynecol 1999; 181:1339.</a></li><li><a class="nounderline abstract_t">Schimpf MO, Abed H, Sanses T, et al. Graft and Mesh Use in Transvaginal Prolapse Repair: A Systematic Review. Obstet Gynecol 2016; 128:81.</a></li><li><a class="nounderline abstract_t">Tate SB, Blackwell L, Lorenz DJ, et al. Randomized trial of fascia lata and polypropylene mesh for abdominal sacrocolpopexy: 5-year follow-up. Int Urogynecol J 2011; 22:137.</a></li><li class="breakAll">American Urologic Association. Urologic surgery antimicrobial prophylaxis. http://www.auanet.org/content/media/antimicroprop08.pdf (Accessed on August 16, 2011).</li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstet Gynecol 2018; 131:e172. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Sanabria A, Domínguez LC, Valdivieso E, Gómez G. Prophylactic antibiotics for mesh inguinal hernioplasty: A meta-analysis. Ann Surg 2007; 245:392.</a></li></ol></div><div id="topicVersionRevision">Topic 8077 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm345221.htm" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : US Food and Drug Administration. 2016 Information for health care providers for stress urinary incontinence. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/ucm345221.htm (Accessed on January 12, 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413126" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36701619" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term Data on Graft-Related Complications After Sacrocolpopexy With Lightweight Compared With Heavier-Weight Mesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Polypropylene Mesh Predicts Mesh/Suture Exposure After Sacrocolpopexy Independent of Known Risk Factors: A Retrospective Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222568" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term mesh erosion rate following abdominal robotic reconstructive pelvic floor surgery: a prospective study and overview of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633316" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical management of pelvic organ prolapse in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27901278" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgery for women with anterior compartment prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104367" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trocar-guided transvaginal mesh repair of pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636208" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vaginal prolapse repair using the Prolift kit: a registry of 100 successive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547113" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : One-year outcome of concurrent anterior and posterior transvaginal mesh surgery for treatment of advanced urogenital prolapse: case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720040" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complications and patient satisfaction after transobturator anterior and/or posterior tension-free vaginal polypropylene mesh for pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720912" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transvaginal mesh surgery for pelvic organ prolapse--Prolift+M: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33239317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : England set to open specialist surgical mesh removal centres in April.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212782" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212782" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777366" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Guidelines for providing privileges and credentials to physicians for transvaginal placement of surgical mesh for pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978115" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical practice guidelines on vaginal graft use from the society of gynecologic surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333818" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice Bulletin No. 176: Pelvic Organ Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23677313" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19701041" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Defining success after surgery for pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24618964" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of 2 transvaginal surgical approaches and perioperative behavioral therapy for apical vaginal prolapse: the OPTIMAL randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858090" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142058" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Surgery for posterior vaginal wall prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105294" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Committee Opinion no. 513: Vaginal placement of synthetic mesh for pelvic organ prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395287" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Optimizing safety and appropriateness of graft use in pelvic reconstructive surgery: introduction to the 2nd IUGA Grafts Roundtable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395288" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Selection of patients in whom vaginal graft use may be appropriate. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395289" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A standardized description of graft-containing meshes and recommended steps before the introduction of medical devices for prolapse surgery. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395290" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Credentialing for transvaginal mesh placement--a case for "added qualification" in competency. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395291" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Informed surgical consent for a mesh/graft-augmented vaginal repair of pelvic organ prolapse. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902825" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association Between the Amount of Vaginal Mesh Used With Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28010989" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32028486" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term Device Outcomes of Mesh Implants in Pelvic Organ Prolapse Repairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36018353" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : PROSPECT: 4- and 6-year follow-up of a randomised trial of surgery for vaginal prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35675593" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transvaginal Mesh Compared With Native Tissue Repair for Pelvic Organ Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37490710" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : European Urogynaecological Association Position Statement: Pelvic Organ Prolapse Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29232268" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pelvic Organ Prolapse Repair Using the Uphold Vaginal Support System: 5-Year Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28577172" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Impact of surgeon experience on routine prolapse operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516812" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Analysis of High-, Intermediate-, and Low-Volume Surgeons When Performing Hysterectomy for Uterovaginal Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27275803" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Surgeon Experience and Complications of Transvaginal Prolapse Mesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601910" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Functional failure of fascia lata allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27275813" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Graft and Mesh Use in Transvaginal Prolapse Repair: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798922" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized trial of fascia lata and polypropylene mesh for abdominal sacrocolpopexy: 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798922" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized trial of fascia lata and polypropylene mesh for abdominal sacrocolpopexy: 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435546" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prophylactic antibiotics for mesh inguinal hernioplasty: A meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
